1 |
McClelland RA, Barrow D, Madden TA et al (2001) Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 142, 2776-2788
DOI
|
2 |
Jones HE, Goddard L, Gee JM et al (2004) Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 11, 793-814
DOI
ScienceOn
|
3 |
Knowlden JM, Hutcheson IR, Jones HE et al (2003) Elevated levels of epidermal growth factor receptor/ c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144, 1032-1044
DOI
ScienceOn
|
4 |
Jin Q and Esteva FJ (2008) Cross-talk between the ErbB/ HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol Neoplasia 13, 485-498
DOI
|
5 |
Chakravarti A, Loeffler JS and Dyson NJ (2002) Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62, 200-207
|
6 |
Liu B, Fang M, Lu Y, Mendelsohn J and Fan Z (2001) Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody. Oncogene 20, 1913-1922
DOI
|
7 |
Morgillo F, Woo JK, Kim ES, Hong WK and Lee HY (2006) Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 66, 10100-10111
DOI
ScienceOn
|
8 |
Sachdev D and Yee D (2006) Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer. J Mammary Gland Biol Neoplasia 11, 27-39
DOI
|
9 |
Carboni JM, Wittman M, Yang Z et al (2009) BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol Cancer Ther 8, 3341-3349
DOI
|
10 |
Haluska P, Carboni JM, TenEyck C et al (2008) HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther 7, 2589-2598
DOI
ScienceOn
|
11 |
Fan QW, Cheng CK, Nicolaides TP et al (2007) A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res 67, 7960-7965
DOI
ScienceOn
|
12 |
Jones RB, Gordus A, Krall JA and MacBeath G (2006) A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 439, 168-174
DOI
ScienceOn
|
13 |
Riedemann J, Takiguchi M, Sohail M and Macaulay VM (2007) The EGF receptor interacts with the type 1 IGF receptor and regulates its stability. Biochem Biophys Res Commun 355, 707-714
DOI
ScienceOn
|
14 |
Ryu JH, Shin M, Kim SA et al (2013) In vivo fluorescence imaging for cancer diagnosis using receptor-targeted epidermal growth factor-based nanoprobe. Biomaterials 34, 9149-9159
DOI
ScienceOn
|
15 |
Yarden Y and Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2, 127-137
DOI
ScienceOn
|
16 |
Rakha EA and Chan S (2011) Metastatic triple-negative breast cancer. Clin Oncol 23, 587-600
DOI
ScienceOn
|
17 |
Lehmann BD, Bauer JA, Chen X et al (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121, 2750-2767
DOI
ScienceOn
|
18 |
Yamasaki F, Zhang D, Bartholomeusz C et al (2007) Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity. Mol Cancer Ther 6, 2168-2177
DOI
ScienceOn
|
19 |
Gallagher EJ and LeRoith D (2010) The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab 21, 610-618
DOI
ScienceOn
|
20 |
Nielsen TO, Hsu FD, Jensen K et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10, 5367-5374
DOI
ScienceOn
|
21 |
DiGiovanni J, Kiguchi K, Frijhoff A et al (2000) Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci U S A 97, 3455-3460
DOI
|
22 |
Carboni JM, Lee AV, Hadsell DL et al (2005) Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res 65, 3781-3787
DOI
ScienceOn
|
23 |
Lee CT, Park KH, Adachi Y et al (2003) Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancer. Cancer Gene Ther 10, 57-63
DOI
ScienceOn
|
24 |
Pollak M (2008) Targeting insulin and insulin-like growth factor signalling in oncology. Curr Opin Pharmacol 8, 384-392
DOI
ScienceOn
|
25 |
Fierz Y, Novosyadlyy R, Vijayakumar A, Yakar S and LeRoith D (2010) Insulin-sensitizing therapy attenuates type 2 diabetes-mediated mammary tumor progression. Diabetes 59, 686-693
DOI
ScienceOn
|
26 |
Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8, 915-928
DOI
ScienceOn
|